April 15, 2024 —A recent publication in Nature Medicine has highlighted the advancements in vaccine design, specifically focusing on Gritstone bio's neoantigen platform, SLATE.

April 15, 2024 —In a recent study, patients with Angelman syndrome demonstrated significant improvements in various areas after treatment with GTX-102.

TransCode Therapeutics, an RNA oncology company, has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1/2 clinical trial for its lead therapeutic candidate, TTX-MC138.

April 15, 2024 — ORIC Pharmaceuticals, a clinical-stage oncology company, has completed the dose escalation phase of its Phase 1b trial for ORIC-114.

Lenvatinib, marketed under the brand name Lenvima, is a multikinase inhibitor specifically targeting vascular endothelial growth factor (VEGF) receptors.

Tirofiban, marketed under the brand name Aggrastat, is a potent medication that belongs to the class of glycoprotein IIb/IIIa receptor inhibitors.

Axicabtagene ciloleucel, branded as Yescarta, is a revolutionary immunotherapy medication developed by Kite Pharma, a subsidiary of Gilead Sciences.

Mometasone topical, commercially known as Elocon, is a potent corticosteroid medication developed by Novartis Pharmaceuticals Corporation.

Canagliflozin, marketed under the brand name Invokana, is a medication developed by Janssen Pharmaceuticals, a division of Johnson & Johnson, for the treatment of type 2 diabetes mellitus.

Blinatumomab, sold under the brand name Blincyto, is a breakthrough cancer treatment developed by Amgen Inc.

Loncastuximab tesirine, marketed under the brand name Zynlonta, is a targeted antibody-drug conjugate (ADC) developed by ADC Therapeutics SA.

Inebilizumab-cdon, commercially known as Uplinza, is an innovative immunomodulatory agent developed by Viela Bio, now a part of Horizon Therapeutics USA.